Samsung Biologics
Search results
One-StopSolutionProvider. Celltrion provides one-stop solutions for the entire process of biopharmaceutical business from R&D to clinical trials, regulatory affairs, production and distribution. Read more. 01.
Celltrion, with an annual production capacity of 250,000L, is the largest manufacturer and exporter of biosimilars in Korea. Along with Remsima, Celltrion's first product, most products on the top 10 export performance list are Celltrion products.
Leveraging a wealth of experience in global clinical trials and mAb expertise, Celltrion has secured regulatory approvals for multiple antibody products in over 100 countries. Operates Korea's largest Global R&D Center capable of biologics and small molecules research.
Mar 15, 2024 · Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients.
Aflibercept. Diabetic macular edema, wet age-related macular degeneration. MFDS (KR) Steqeyma®. Ustekinumab. Psoriasis, inflammatory bowel disease. MFDS (KR) It is not intended for product promotion or sales. For more information, contact your doctor or healthcare professional.
Celltrion is a leading global biopharmaceutical company that researches, develops and manufactures antibody biosimilars, new biologics and small molecule drugs. We have presented a new paradigm to the global biologics market with the launch of the world’s first antibody biosimilar.
The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma®, Yuflyma® and Omlyclo®, FDA approval for Zymfentra®, and EC approval for Remsima® SC.
Jan 11, 2024 · Celltrion looks beyond biosimilars to bring value to healthcare and to pioneer innovation. Company outlines key business strategies, including expanded product pipeline and healthcare intelligence bank, building upon groundbreaking legacy of success in biosimilars.
Jan 17, 2024 · About Celltrion USA. Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients.
The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma®, Yuflyma® and Omlyclo®, FDA approval for Zymfentra®, and EC approval for Remsima® SC.
